BAAR, Switzerland--(BUSINESS WIRE)--Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study.
Stallergenes Greer, a global leader in allergy therapeutics, will present positive results from its SPEED survey at the upcoming CFA congress (Congrès Francophone d'Allergologie, the French congress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback